ASX Growth Companies With High Insider Ownership And Revenue Increases Up To 76%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 24 2024
0mins
Source: Yahoo Finance
- Top 10 Growth Companies With High Insider Ownership In Australia:
- Lists companies like Hartshead Resources, Cettire, and Gratifii with insider ownership and earnings growth percentages.
- IperionX:
- Australian growth company focusing on mineral properties with high insider ownership.
- Navigating a transformative phase with significant revenue growth forecasted.
- Strategic partnerships in the U.S. enhancing its potential in niche markets.
- Mesoblast:
- Australian biotech firm trading at a discount with rapid revenue and profit expansion forecasts.
- Promising clinical advancements and insider buying contributing to growth.
- Technology One:
- Australian software company with high insider ownership showing promising financial trajectory.
- Earnings have increased, and revenue is rising, indicating potential value relative to peers.
- Next Steps:
- Access a comprehensive list of 89 fast-growing ASX companies with high insider ownership.
- Simplify portfolio management with Simply Wall St for critical updates on stocks.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 35.00 USD with a low forecast of 35.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.770
Low
35.00
Averages
35.00
High
35.00
Current: 18.770
Low
35.00
Averages
35.00
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
